Interleukin-6 and severity of COVID-19 patients in Hefei, China - 22/09/20

Doi : 10.1016/j.medmal.2020.06.005

Z. Zhao ^a,^{^{1
These authors contributed equally to the present study.}}, J. Xie ^b,^{^{1
These authors contributed equally to the present study.}}, M. Yin ^c,^{^{1
These authors contributed equally to the present study.}}, Y. Yang ^c, C. Ding ^a, Y. Gao ^a,⁎ , X. Ma ^d,^⁎
^a Department of Infectious Diseases, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China
^b Department of Dermatology, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China
^c Department of ICU, Hefei Infectious Diseases Hospital, Hefei, Anhui, 230000, China
^d Department of Laboratory Medicine, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China

^⁎Corresponding author at: Department of Infectious Diseases, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.Department of Infectious Diseases, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of ChinaHefeiAnhui230001China^⁎⁎Co-corresponding author at: Department of Laboratory Medicine, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.Department of Laboratory Medicine, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of ChinaHefeiAnhui230001China

conectar o crear una cuenta

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Highlights

•	Twenty-four out of 75 patients developed into severe condition in the course of the infection.
•	The prominent laboratory abnormalities of COVID patients were lymphopenia, elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH).
•	Elevated interleukin 6 (IL-6) correlated with decrease of LYM%, CD4⁺ and CD8⁺ T cell counts, and increase of CRP, LDH and Procalcitonin (PCT) levels.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, Severity, Interleukin 6